Cullinan Oncology Inc. and Taiho Pharmaceutical Co., Ltd. announced an agreement through which Taiho will acquire Cullinan Pearl Corp. and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417, an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations, while sparing cells expressing wild-type EGFR in non-small cell lung cancer.
Before any strategy can be formulated for next year’s appropriations, cancer groups must confront the formidable challenge of figuring out how much of President Joe Biden’s vision for cancer research is realistic.
In the trenches on the medicine wards and smoking cessation clinics at Parkland Hospital and UT Southwestern Simmons Cancer Center, I see firsthand the increased prevalence of smoking in the Black population, their frequent use of menthol, and the ravaging toll it takes on their health.
Deaths from uterine cancer are rising in the U.S., and are highest among non-Hispanic Black women, according to a new study led by researchers at NCI. The higher death rates are related to the rising incidence of aggressive subtypes of uterine cancer.
Two studies led by researchers at the American Cancer Society showed an increase in the use of proton beam therapy for patients with cancer in the U.S. during the past decade.
A study led by researchers at ACS showed cancer survivors in the United States who reported medical financial hardship have a higher mortality risk than cancer survivors without financial hardship. Medical financial hardship was measured as problems affording health care or delaying or forgoing any health care due to cost in the past 12 months.
Findings led by researchers at the American Cancer Society show that five-year survivors of adolescent and young adult cancer in the United States have a higher risk of developing and nearly double the risk of dying from a new primary cancer as the general population.
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer, according to a large randomized clinical trial conducted by researchers from SWOG Cancer Research Network.
The American Society of Clinical Oncology published new guidelines to support clinicians in managing immune-related adverse events in adult cancer patients treated with CAR T-cell therapy.
Researchers from the Gwangju Institute of Science and Technology have developed a deep learning model that predicts unexpected drug-drug interactions (DDIs) based on their effects on gene expression.
